Title: Learning good therapeutic targets in ALS, neurodegeneration, using observational studies

1234567 Mohammadali Alidoost¹, Jeremy Y. Huang², Georgia Dermentzaki³, Anna S. Blazier,³ Giorgio Gaglia², Timothy R. Hammond³, Francesca Frau⁴, Mary Clare Mccorry⁵, Dimitry Ofengeim³, Jennifer L. Wilson^{1*}

- Affiliations:
- 1. Department of Bioengineering, University of California Los Angeles, Los Angeles, CA, 90095, USA
- 8 2. Precision Medicine & Computational Biology, Sanofi Research US, Cambridge, MA, 01701, USA
- 9 3. Rare & Neurologic Diseases, Sanofi Research US, Cambridge, MA, 01701, USA
- 10 4. Evidence Generation & Decision Sciences, Sanofi Development, Frankfurt, 65929, Germany
- 11 Scientific Relations & Initiatives, Sanofi Research US, Cambridge, MA .01701, USA
- 12 * To whom correspondence should be addressed: Jennifer L Wilson, jenniferwilson@g.ucla.edu, 420 13 Westwood Plaza, 5121 Eng V, Rm 4121D, Los Angeles CA, 90095, USA
- 14 Funding
- 15 This project was supported by a Sanofi iDEA-iTECH award.

16 **Competing interests**

- 17 The authors Jeremy Y. Huang, Georgia Dermentzaki, Anna S. Blazier, Giorgio Gaglia, Timothy R.
- 18 Hammond, Francesca Frau, Mary Clare Mccorry, and Dimitry Ofengeim are Sanofi employees and may
- 19 hold shares and/or stock options in the company.
- 20 Keywords: network biology, real-world data, systems modelling, neurodegeneration
- 21

24 Abstract 25 A

Analysis of real-world data (RWD) is attractive for its applicability to real-world scenarios but 26 RWD is typically used for drug repurposing and not therapeutic target discovery. Repurposing studies 27 have identified few effective options in neuroinflammatory diseases with relatively few patients such as 28 amyotrophic lateral sclerosis (ALS), which is characterized by progressive muscle weakness and death 29 with no disease-modifying treatments available. We previously reclassified drugs by their simulated 30 effects on proteins downstream of drug targets and observed class-level effects in the EHR, implicating 31 the downstream protein as the source of the effect. Here, we developed a novel ALS-focused pathways 32 model using data from patient samples, the public domain, and consortia. With this model, we simulated 33 drug effects on ALS and measured class effects on overall survival in retrospective EHR studies. We 34 observed an increased but non-significant risk of death for patients taking drugs associated with the 35 complement system downstream of their targets and experimentally validated drug effects on 36 complement activation. We repeated this for six protein classes, three of which, including multiple 37 chemokine receptors, were associated with a significant increased risk for death, suggesting that 38 targeting proteins such as chemokine receptors could be advantageous for these patients. We recovered 39 effects for drugs associated with complement activation and chemokine receptors in Parkinson's and 40 Myasthenia Gravis patients. We demonstrated the utility of network medicine for testing novel therapeutic 41 effects using RWD and believe this approach may accelerate target discovery in neuroinflammatory 42 diseases, addressing the critical need for new therapeutic options.

43 44

45 Introduction

We need novel treatment identification methods for rare, difficult-to-treat diseases, especially those with insufficient experimental systems. Big data approaches and advanced algorithms have the power to capture patient data and infer new disease drivers in ways previously not possible. Many approaches suffer from limitations that were well-established a decade ago: animal models are valuable for understanding mechanism but have limited relevance to human conditions, human epidemiology is highly relevant to human disease but is insufficient for explaining causality, and natural conditions are the most relevant and may explain causality but are rare¹. We hypothesized that a model-informed analysis of

53 patient data may overcome these hurdles, by predicting causality first, and later testing causal predictions 54 in relevant human disease contexts, thereby overcoming the limitations of traditional approaches. 55 Retrospective analyses of electronic health records (EHRs) are attractive for difficult-to-treat 56 conditions, including many neuroinflammatory conditions, where animal and model systems have failed to 57 deliver treatments with substantial impacts on survival. However, when inferring treatment impact from 58 real-world evidence, most studies are restricted to repurposing of known druggable targets. For instance, 59 the discovery of phosphodiesterase inhibitors as protective for Parkinson's² and amyotrophic lateral 60 sclerosis (ALS)³, peroxisome proliferator-activated receptor (PPAR) agonists as protective in Alzheimer's 61 Disease⁴, and the potential of multiple drugs, diazoxide, gefitinib, paliperidone, and dimethyltryptamine as 62 high-quality candidates for repurposing in ALS⁵ all leverage 'omics data, network medicine, and EHRs, 63 but they uncovered evidence for known, druggable targets. Indeed, reviews of the field emphasized that 64 real world data can support clinical trial emulation, sub phenotyping, or image analysis⁶, but the authors 65 failed to consider the historical record as sufficient for supporting novel, untested drug targets. Despite 66 the status quo, we had compelling prior evidence that it might be possible to more directly vet novel 67 targets in EHRs and sought to test that idea in difficult-to-treat neuroinflammatory populations. 68 Specifically, we learned that disease-specific network models improved prediction of drug effects⁷ and 69 that drug-effect predictions based on shared protein networks were detectable in EHRs⁸. 70 Debilitating neuroinflammatory conditions without substantially effective treatments have 71 motivated creative and compelling approaches to advance treatment options. Of the seven approved 72 treatments for ALS by the Federal Drug Administration (FDA), none are disease-modifying⁹ and none 73 prevent death. Multiple studies have identified distinct molecular mechanisms including the role of the 74 innate immune system (Table S4), among other genetic drivers ^{9,10}. Targeting these disrupted pathways 75 or causal genetic drivers in the clinic has had limited efficacy and coverage due to the time to develop 76 new medicines and initiate new trials. Since ALS is a rare disease, clinical trial cohorts often struggle to

77 meet statistically significant thresholds, leading to increased interest in leveraging new insights from real-

world-data. Thus, we pursued our approach in neuroinflammatory conditions because of the potential for
 accelerating discovery for these devastating conditions.

80 In this study, we tested our network inference platform on neuroinflammatory conditions and 81 corroborated our model predictions EHR investigation with experimental analysis. Intriguingly, our results 82 synergize with other investigations of dysregulated pathways in ALS, specifically, we recovered increased 83 risks for death associated with complement system activation. And despite the fact that ALS patients 84 were not prescribed any complement-targeted drugs, our retrospective analysis provided rationale for 85 directly inhibiting this pathway. We also asked whether these insights were generalizable across 86 additional neuromuscular and neurodegenerative diseases with larger patient populations, such as 87 Myasthenia gravis and Parkinson's disease. In total, we built and tested six network classes with different 88 observed significant impacts on overall patient survival in several modules. Encouragingly, our pipeline 89 independently identified therapeutic targets currently in clinical development and suggested additional 90 targets with stronger effects. By classifying approved therapies by their effects on downstream proteins, 91 rather than labeled primary targets, we can leverage large-scale cohort studies to identify novel targets 92 for ALS and other neurodegenerative diseases.

93

94 Materials and Methods

95 Curating ALS-associated neurogenerative disease pathways

To customize our network analysis, we curated novel disease pathways from multiple sources. All together, we included 195,252 gene-phenotype relationships across 1,096 unique disease pathways and 24,441 unique genes/transcripts. We curated this data from six sources listed below. Further, a list of all derived pathway names, their sources, and the total number of genes is included in **Supplemental File 2**. For a detailed list of pathway sources and processing for each source, and integration into our network modeling platform please see *Supplemental Methods*.

102

103 Running ALS-PathFX on all approved drugs

Like previous versions of PathFX, the ALS version required drug binding proteins as inputs. We used drug target information from DrugBank version 5.1.6. as inputs for ALS-PathFX analysis. We generated networks and association tables for all drugs and then searched the PathFX-generated association tables for phenotypes of interest. The association tables are standard outputs from PathFX

and included all network-associated phenotypes, the multiple-hypothesis-corrected p-values for the
associations, and which disease pathway proteins were discovered in the networks. All ALS-PathFX
predictions, created by merging all associations tables for drugs analyzed, are included in Supplemental
File 2.

113 Generating network classes

114 Using the merged table of all ALS-PathFX drug-phenotype associations, we counted how often a 115 network protein was used to make a drug-phenotype prediction (e.g., CXCL13 was used to predict a 116 network association from gabapentin to the "MS CSF" and "Bulk RNAseq ALS vs Control" pathways, and 117 C3 was used to predict a network association from gabapentin to the "Bulk RNAseg ALS vs Control" 118 pathway). After identifying network proteins occurring in the most drug-ALS PathFX associations, we 119 developed new drug classes by grouping drugs that shared network proteins (e.g., CXCL13 or C3). We 120 completed this analysis using the pandas module in python. Because we wanted to study patient data, we 121 also filtered out experimental or unapproved drugs and counted the number of approved active 122 ingredients with each network protein.

123 In a few instances, we observed several related network proteins and made multi-protein classes 124 based on gualitative and guantitative assessment of the ranked proteins, such as in the case for the 125 complement system proteins and chemokine proteins. Grouping drugs based on network proteins yielded 126 groups for the "target" cohorts ("network" class). To generate comparable "comparator" cohorts, we 127 assessed all remaining approved drugs that had network associations to the same ALS phenotypes, but 128 lacked a network protein in the association ("non-network" class). For instance, all drugs with an 129 association to the "MS CSF" or "Bulk RNAseq ALS vs Control" pathways would be considered in the non-130 CXCL13 comparator class. All network proteins and their presence in drug networks are contained in 131 Supplemental File 3). Code for this analysis is included in our GitHub.

132

133 Clinical data – Optum Market Clarity

We used the Optum's Market Clarity data: Optum® Market Clarity Data is an innovative dataset
 of integrated multi-source medical and pharmacy claims and electronic health record (EHR) data that

136 enables detailed evaluation and assessment of the patient journey. The Market Clarity Data Asset 137 combines robust transactional pharmacy and medical claims data with best-of-breed EHR data. It is a 138 fully HIPAA-compliant, statistician-certified, de-identified precision data set that uncovers hidden 139 intelligence to turn insights into quick action. The Market Clarity Dataset links EHR data with historical, 140 linked administrative claim data, pharmacy claims, physician claims, facility claims (with clinical 141 information) and is inclusive of medications prescribed and administered. Clinically rich and specific data 142 elements sourced from the EHR include lab results, vital signs and measurements, diagnoses, 143 procedures and information derived from unstructured clinical notes using natural language processing. 144 We specifically assessed patient records available through February 2023 and accessed the 145 following data tables - the membership info for collecting date of birth, sex, race, ethnicity, and gender, 146 when available; the RX claims table to assessing filled prescriptions as a proxy for drug exposures; the 147 diagnosis table for identifying ALS patients and other comorbid conditions; and the date of death table for 148 collecting the month/year of death, when available. 149 150 Observational studies in the electronic health record

To measure effects for our network-derived drug classes, we used a standard target-comparator approach using best practices in propensity score estimation and weighted treatment effects. We've used a similar approach in our own work⁸ and describe the approach in greater detail in *Supplemental Methods*.

155

156 Stem Cell Culture

Human iPSC astrocytes (iCell astrocytes, Fujifilm, Cat# C1037) were cultured in Matrigel-coated
 (Corning 354277) 96-well plates with DMEM/F12 (Life Technologies 11330057) media supplemented with
 heat-inactivated FBS (Gibco A38400-01) and N-2 supplement (Gibco 17502-048).

160 Stimulation and drug treatment

161 Three days post-plating, iCell astrocytes were treated with selective compounds (Table S2) at
162 100 nM, 1μM, and 10 μM concentrations. For astrocyte stimulation (A1 subtype) we used the A1 cocktail:
163 IL-1a (R&D Systems, Cat# 200-LA, 0.3 ng/mL), TNF alpha (R&D Systems, Cat# 210-TA, 3 ng/mL) and

164	C1q (MyBiosource, Cat# MBS147305, 40 ng/mL) factors. Both the compounds, at multiple doses (100
165	nm, 1 uM, and 10 uM), and the A1 cocktail factors were added simultaneously on the cultures for
166	overnight treatment (24h).
167 168	ELISA for complement system activation
169	Media were collected 24h post-treatment and complement levels were assessed with the Milliplex
170	Human Complement Panel 1 (Millipore, HCMP1MAG-19K / Factors: C1q, C3, C3b/iC3b, C4, Factor B,
171	Factor H) and 2 (Millipore, HCMP2MAG-19K / Factors: C2, C4b, C5, C5a, Factor D, Mannose-binding
172	lectin (MBL), Factor I) according to the kit's instructions. The assay was run in a Bio-Plex 2000 instrument
173	(Biorad).
174	Data availability
175	The Market Clarity data used were licensed from Optum and are not publicly available.
176	To increase the rigor and reproducibility of our work, we have released code and data for the network
177	analysis, and anonymized code for accessing clinical data through a GitHub repository:
178	https://github.com/jenwilson521/network_drug_classes_als/ All supplemental Excel files are included in
179	their original format in the GitHub repository to increase readability and reusability of the data.
180 181 182	Results ALS-PathFX predicted drug network associations to ALS through distinct proteins
183	Our overall approach used pathway modeling to identify novel drug classes and observational
184	studies in the health record to test the utility of these drug classes (Figure 1). To build a custom network
185	medicine platform, we curated several high-quality datasets from the TargetALS data portal and several
100	

187 from multiple tissue types including cerebellum, motor cortex, and spine. We derived multiple gene sets

188 from this data using different fold-change thresholds (see *methods*). We also leveraged multiple novel

- 189 sequencing and proteomics data derived from patient samples, including snRNAseq in multiple tissue
- 190 types, proteomics from patient cerebral spinal fluid (CSF), and RNAseq data from reactive astrocytes and
- 191 microglia (for a full list see *methods* and¹¹). We specifically modified our highly-flexible PathFX platform
- 192 (released with ¹²) to emphasize these gene lists (referred to as "pathway phenotypes") into PathFX¹²⁻¹⁴

using the original bias reduction methods published in ¹³ and described in methods. We then used our custom network algorithm, ALS-PathFX, to model drug effects and derive new drug classes based on predicted effects on nearby, but untargeted (not bound by drug) proteins (**Figure 1B**). Taken together, our ALS-PathFX network model leverages several high-quality disease-relevant datasets to make predictions about drug effects.

198 We generated ALS-PathFX networks for 7,013 approved and experimental drugs using targets 199 from DrugBank^{15,16}. Briefly, ALS-PathFX first identified high-confidence proteins downstream of druggable 200 targets, using interaction specificity analysis, a process that prioritizes protein interactions while reducing 201 connections through hub proteins. After generating a protein network for each drug, ALS-PathFX 202 identified network-associated phenotypes, by assessing which disease pathway proteins were enriched in 203 the drug network relative to the entire interactome, and using multiple hypothesis correction and 204 controlling for biases in the number of pathway-associated genes/proteins (as described in ¹³ and in 205 methods). In total, we discovered 13,967 drug-phenotype associations containing 2,984 unique drugs 206 and 90 unique disease pathways. For example, PathFX generated a network of 235 proteins and 238 207 edges for the antipsychotic, acetophenazine, and connected the network to 138 phenotypes, including 4 208 neurodegenerative phenotypes (subnetwork associated with four phenotypes shown in Figure 2). 209 Acetophenazine's network contained the complement system proteins Complement C3 (C3), 210 Complement C5 (C5), Complement C5a Receptor 1 (C5AR1), and Complement C3a Receptor 1 211 (C3AR1). Network proteins may be associated with more than one phenotype, and for instance, C3 and 212 C3AR1 were associated with "Multiple sclerosis" and "sequencing data 1". We assigned acetophenazine 213 to the "complement-associated drug class" or "CS-class" for brevity. We considered any drugs predicted 214 to affect the same phenotypes (e.g., "Multiple sclerosis" or "sequencing data 1") but without complement 215 proteins in their networks, as sufficient comparator drugs and considered them in the "non-CS-class" of 216 drugs. We provide more detail about ALS-PathFX results and assessment of network-protein drug 217 classes in the Supplemental Results.

218

219 Complement-system-associated drugs are associated with changes in survival

220 We hypothesized that drugs with complement system proteins in their networks would have 221 distinct clinical effects. This hypothesis is further supported by multiple recent developments of 222 complement system inhibitors for neurodegenerative disease, specifically myasthenia gravis (Table S4). 223 Aside from recent discoveries, complement system inhibitors have been approved since 2007 for several 224 other non-neurodegenerative diseases including autoimmune and blood disorders (Table S4). Despite 225 several approved compounds, none were prescribed in our ALS study patient population (described 226 below and depicted in Figure S6A, all compounds listed in Supplemental File 4), further emphasizing 227 the need for a way to anticipate their effects on overall survival.

228 To test whether ALS-PathFX-predicted drugs affected overall survival, we conducted a novel 229 observational study a using standard treatment-comparator study design and large-scale propensity 230 scoring to adjust for possible confounding variables. More specifically, we accessed the de-identified 231 Optum Market Clarity data. Optum Market Clarity deterministically links medical and pharmacy claims 232 with EHR data from providers across the continuum of care. This data is available for researchers without 233 IRB approval (longer description in Methods). The novelty in our approach was deriving network-protein-234 based drug classes instead of using traditional drug classifications such as anatomical therapeutic 235 category (ATC) classification systems. We provide a more intuitive description of this process in the 236 Supplemental Results.

237 After controlling for possible confounding (Figure S6), we estimated the differences in overall 238 survival and observed a marginal, decreased, but not significant survival time for patients with an 239 exposure to CS-class drugs (HR = 1.031 95% confidence interval (0.937, 1.134), p = 0.534) (Figure 3A, 240 Table 1). The study discovered a detrimental effect early, where CS-class drugs are separated from non-241 CS-class drugs before ~2,000 days (~5.5 years). At later timepoints, ~10,000 days (~27.4 years), overall 242 survival was minimally distinguishable. While the result is modest and insufficient to directly change 243 clinical practice, this result affirmed that network-derived drug classes could predict differential effects on 244 ALS survival in historical patient cohorts and suggested the possibility of testing other network drug 245 classes. Yet, as mentioned previously, the results do not confirm whether drugs activate or inhibit the 246 complement system.

247

248 Network derived drug classes activate complement system proteins

249 We next sought additional data sources and experiments to better understand possible drug-250 induced effects on the complement system. We first sought drug-induced gene expression changes from 251 two public data sources. PharmOmics²¹ and LINCS²² (Supplemental methods) and saw little or 252 ambiguous effects in these data sources (supplemental results). We next hypothesized that protein-level 253 changes may better inform the observed effect on overall survival. We investigated complement levels 254 using ELISA, specifically measuring C3, Complement 4 (C4), and factor B levels released from healthy 255 stem cells following exposure to drugs from our network and non-network classes (Figure 4). Healthy 256 stem cells were a sufficient system because we started following patients before their ALS diagnosis and 257 this could indicate whether study drugs induced or suppressed complement system proteins. We 258 prioritized compounds for experimental testing based on those that had the highest number of unique 259 patients and total exposure days per patient (reflecting repeat prescription claims). The CS-class drugs, 260 mirtazapine and methylprednisolone increased activation of both C3 and C4, and the CS-class drug, 261 gabapentin, appeared to have no effect on either C3 and C4. Of the non-CS-class drugs tested, 262 cephalexin, amoxicillin, cefuroxime, nitroglycerin, and solatol had no effect on C3 or C4 levels, however, 263 the non-CS-class drugs, famotidine and erythromycin, increased C3 and C4 levels (Figure 4). Drugs from 264 both classes seemed to induce Factor B, but to a lesser effect. Some of these effects are supported by 265 additional literature such as different methylprednisolone regiments in myasthenia gravis patients led to 266 an increase in C3 and C4 levels²³. This increase in C3, C4 and Factor B for the above compounds 267 indicate that these compounds induce further complement activation once complement activation is 268 initiated, since treatment of human iPSC astrocytes alone w/o the A1 cocktail factors did not elicit any 269 complement response (undetectable levels).

In our network model, methylprednisolone, gabapentin and mirtazapine have distinct network connections to the complement system proteins, C3, C5, complement C3a receptor (C3AR1), and complement C5a receptor (C5AR1). Specifically, methylprednisolone, gabapentin, and mirtazapine connected through annexin A1 (ANXA1), the adenosine A1 (ADORA1) receptor, and the opioid receptor kappa 1 (OPRK1), respectively (all pathway connections in **Supplemental File 2**). This suggests that alternative pathways could have differential effects on the complement system, but that the observed trends in overall survival might be associated with increased activation of the complement system.

277

278 Several network classes alter overall survival in ALS-patients

279 We repeated our observational study analysis pipeline for an additional 5 drug classes and 280 ranked their overall effects on survival (Figure 3B-H, Table 1). We observed a large number of 281 prescription-days per study drug as observed with the complement system study, though, the exact brand 282 names changed per study (Table S6, Figures S9, S11, S13, S15, S17). Again, we saw low predictive 283 performance of the logistic regression, suggesting good covariate balance (Table S7), and similar 284 propensity score plots, suggesting sufficient class balance (Figures S10, S12, S14, S16, S18). Across all 285 drug classes, we saw an increased risk for death in the network drug class compared to the non-network 286 classes (Figure 3G,H, Table 1). The CXCR5 class had the greatest increased risk of death (HR = 1.151, 287 95% confidence interval (1.021-1.298), p = 0.0214) (Figure 3B), and the chemokine class had the next 288 highest risk (HR = 1.123, 95% confidence interval (1.018-1.239), p =0.0202) (Figure 3C). The CNR2 289 class had a marginally decreased, but not significant risk (HR = 0.994, 95% confidence interval (0.890-290 1.097), p = 0.897), most similar to the value observed for the complement system drug class. All other 291 survival curves provided in Figures S19-S21. All of the retained brand names, the number of unique 292 patients with an RX claim, the prescription-days per drug, and patient demographics are included in the 293 extended supplement for each network class comparison: chemokine (Supplemental File 6), CXCR3 294 (Supplemental File 7), CXCR5 (Supplemental File 8), CNR2 (Supplemental File 9), and NPY 295 (Supplemental File 10). All hazard ratios also reported in Supplemental File 16. We also investigated 296 the extent to which network drug classes shared brand names and observed shared, but distinct brand 297 names in each drug class comparison as measured by Jaccard similarity (Figure S22C, D, Supplemental 298 methods and results).

299

300 Network-drug classes affect overall survival in multiple neurodegenerative diseases

301 An intriguing utility for our analysis could be in identification of key nodes of pathophysiology 302 across multiple diseases on the nervous system. We first demonstrated that neurodegenerative diseases 303 shared pathways information using network models (**Figure S23**, *Supplemental methods and results*). 304 Intriguingly, neurodegenerative diseases share more genes near druggable targets than if comparing all

305 disease genes. We thus repeated measurements for some network classes in multiple disease 306 indications. We specifically considered effects of the complement system in myasthenia gravis and 307 Parkinson's disease and the CXCR3, and CXCR5 classes in myasthenia gravis. We again assessed 308 prescription days per drug for all studies (Table S6, Figures S24, S26, S28, S30), measured low 309 predictive performance of a logistic regression analysis (Table S7, and saw similar propensity score plots 310 between target and comparator cohorts (Figures S25, S27, S29, S31). Interestingly, we observed a 311 similar trend for myasthenia gravis patients taking the complement system drugs where early survival 312 (before ~2,000 days) showed separation between the CS-class and non-CS-class drugs, however, the 313 curves crossed-over at later timepoints (~10,000 days), suggesting a protective effect of complement-314 associated drugs at early time points. Unlike our analysis in ALS patients, this analysis yielded a slight, 315 but significant increased risk for death (HR 1.098, 95% confidence interval (1.018-1.183), p = 0.015) 316 (Figure 3D). This finding combined with our experimental results and the recent approvals of complement 317 inhibitors for myasthenia gravis further suggest that activated complement is detrimental for overall 318 survival in neurodegeneration, but only at early timepoints. The effect of CXCR5 drugs was similar in 319 myasthenia gravis patients relative to ALS patients (HR 1.143, 95% confidence interval (1.052-1.241), p = 320 0.00155) (Figure 3E) and the effect of CXCR3 drugs was greater than in ALS patients (HR 1.321, 95% 321 confidence interval (1.223-1.427), $p = 1.47 \times 10^{-12}$) (Figure 3F). The effect of complement-system drugs 322 in Parkinson's patients showed, similar, but starker cross-over effects like we observed in ALS and 323 myasthenia gravis patients. We observed no overall survival benefit or risk (HR 0.992, 95% confidence 324 interval (0.965-1.020), p = 0.579) (Figure S32). Like before, all of the retained brand names, the number 325 of unique patients with an RX claim, the prescription-days per drug, and patient demographics are 326 included in the extended supplement for each network class comparison: CXCR5 in myasthenia gravis 327 (Supplemental File 12), CXCR3 in myasthenia gravis (Supplemental File 13), complement system in 328 myasthenia gravis (Supplemental File 14), and complement system in Parkinson's (Supplemental File 329 15).

330

331 Discussion

332 We presented an approach for using proteins downstream of druggable targets to define new 333 drug classes and tested the effects of these drug classes on overall survival in ALS and two additional 334 neurodegenerative diseases. We used observational studies as exploratory analyses, and while they 335 would require further, dedicated clinical investigations to confirm their effects, they are compelling for their 336 ability to recover known effects - specifically the effect of complement activation as detrimental to survival 337 in ALS, myasthenia gravis, and Parkinson's disease. Our preliminary experimental data combined with 338 recent approvals of complement inhibitors for myasthenia gravis patients (Table S4) further supports the 339 potential of complement inhibitors in ALS. Overall, this suggests a novel and impactful approach for 340 identifying disease-drivers in rare and difficult-to-treat diseases and may provide valuable insights to 341 therapeutic target selection.

342 Our results are further compelling for their utility in difficult-to-treat populations. ALS is 343 insufficiently explained by genetics, with less than 10% of familial and sporadic ALS cases explained by 344 genetic drivers^{9,10}. Without sufficient molecular targets, novel approaches are desperately needed to 345 identify treatment strategies for the disease. Further, the ALS population is relatively small and is typically 346 insufficient for observational studies. Indeed, through a related project, the Veterans Affairs dataset, 347 which contained nearly 20,000 ALS patients, is the largest repository of historical ALS patient data and is 348 nearly double the size of the cohort in this study²⁴. Yet, we still resolved statistically-significant clinical 349 effects by emphasizing proteins downstream of druggable targets, which allowed the inclusion of more 350 patients.

351 While we believe our paradigm can greatly enhance model-informed drug development efforts, 352 further work could overcome limitations in our current study. For instance, we had insufficient network 353 connections to all possible druggable targets and were limited to deriving network classes for proteins 354 that were "close" to approved targets. Our network drug classes also shared many approved drugs 355 indicating that our current interaction network was only sufficiently connected to some pathways. 356 However, the differences in network phenotypes effectively separated drugs to discern relatively stronger 357 effects, such as the increased risks associated with CXCR5 networks. This emphasizes the importance of 358 deriving high-quality, disease pathway phenotypes. We also tested these network classes in a single 359 patient population and further testing using data from additional health systems could elevate the impact

360 of these findings. Indeed, previous meta-analyses across healthcare systems have successfully 361 discovered drug-class effects on cardiovascular disease outcomes²⁵. Further, an intriguing opportunity, or 362 possible challenge, of historical data analysis is how to interpret the outcomes in the context of EHR 363 timescales and understand their relevance to dedicated clinical investigations. We followed patients for 364 nearly two decades, when most clinical trials are months to years in duration. Of the four FDA-approved 365 therapies for ALS, the riluzole trials measured outcomes at 12 months²⁶ or 18 months follow-up²⁷ and the 366 trials for edavarone, phenylbutyrate-taurursodiol (PB-TUDCA), and torfersen measured changes in the 367 revised ALS functional rating scale²⁸ at shorter durations – ranging from 24-28 weeks^{9,29–32}. Our 368 measured differences in proportions of surviving patients at short durations (~2 years) are similar to effect 369 sizes in the riluzole trials, suggesting that future observational studies, which leverage drug network 370 classes, could shorten observation times to better anticipate effect sizes measurable in the duration of a 371 clinical study.

372 Our discovery of disease drivers complements an evolving landscape of shared molecular 373 underpinnings of clinically-distinct diseases. Specifically, we predicted that activated complement would 374 increase risk for death across multiple disease indications. Our pathways analysis of shared 375 dysregulation is supported by other findings, specifically, Arneson et al³³ noted that when disease genes 376 and proteins weren't shared across neurodegenerative diseases, gene and protein functional information 377 was shared, further emphasizing shared dysregulation across neurodegenerative diseases. Separate 378 investigations of post-mortem brain samples further corroborated shared gene-level changes across 379 patients with four neurodegenerative diseases (Alzheimer's Disease, Parkinson's disease, Huntington's 380 disease, and ALS) and discovered that shared genes were involved in functional processes such as 381 inflammation, mitochondrial dysfunction, and oxidative stress^{33,34}. Additionally, multiple canonical 382 inflammatory reactivity inducers, including complement subcomponent C1q, interleukin 1 alpha (IL-1 α), 383 and tumor necrosis factor (TNF), convert astrocytes into A1 reactive astrocytes³⁵, and these 384 proinflammatory, reactive astrocytes secrete multiple complement factors, reduce synaptic and neuronal 385 connectivity, and are linked extensively to neurodegenerative disease³⁶. Taken together, this further 386 supports the possibility of shared molecular changes in these diseases, though, further experimental 387 validation would be required to confirm this general finding.

388 Our approach motivates extending the integration of clinical health data into Model Informed Drug 389 Development (MIDD). Already, the FDA has provided guidance about the use of real-world data (RWD) 390 for generating real world evidence (RWE) from sources other than randomization, controlled trials 391 (RCTs)(**Table S9**). Indeed, many have generated RWE to support regulatory decision making including 392 accelerated approvals, learning intrinsic factors, and optimizing dosing (**Table S9**). Yet these studies did 393 not leverage RWD for novel target support.

394 Other sources have identified novel targets from RWD, although, they have focused directly on 395 target-driven effects instead of downstream effects. Genetic data repositories have helped identify lead 396 candidates from patient data, such as in the case of Proprotein convertase subtilisin/kexin type 9 397 (PCSK9) inhibitors where inactivating and gain-of-function mutants were associated with elevated or 398 reduced cholesterol, respectively^{37,38}. Mendelian randomization is another method of inferring drug-target 399 effects in new populations³⁹, but not every suitable target has sufficient genetic connections to support 400 later therapeutic development. Additionally, analysis of PheWAS and expression quantitative trait loci 401 (eQTLs) have also coupled gene variation with observable clinical effects, especially side-effects^{40,41}. In 402 contrast to our approach, these approaches overlook downstream effects and require sufficient genetic 403 variation in patient populations to advance therapeutic discovery.

For the most part, prior work combining molecular models of drug effects with patient data have been limited to drug repurposing studies, and we believe our approach greatly expands the possibilities for learning promising therapeutic targets from real-world patient data. Knowing that electronic health records will be increasingly useful to support new target identification, we anticipate that network medicine will extend capabilities beyond target-centric approaches.

409

410 Study Highlights

411 Currently, the impact of real-world data (RWD) on druggable targets with translational impact is limited to 412 drug-repurposing. However, we hypothesized that network models of drug-induced signaling could 413 elevate the impact of RWD for identifying novel drug targets. This study addressed the feasibility of that 414 approach by simulating the effects of novel targets and testing these effects in neuroinflammatory 415 conditions. We demonstrated that drugs that alter complement activation have deleterious effects on

- 416 overall survival and these results are consistent with effects of recently FDA-approved drugs, although
- 417 none of our patients were taking them. We believe this paradigm will change translational science in how
- 418 RWD may be used to identify novel, druggable targets.

419 Acknowledgments

- 420 The authors would like to acknowledge the Sanofi real world data team, and especially Thomas Verrier,
- 421 the RWD-Platform Support team for their invaluable support navigating data access, without which, the
- 422 study could not be completed.

423 **Contribution statement**

- 424 J.L.W., M.A., J.Y.H., G.D., A.S.B., F.F., D.O. wrote the manuscript. J.L.W., J.Y.H, G.D., A.S.B., D.O.
- 425 designed the research. J.L.W., J.Y.H., M.A., G.D. performed the research. J.L.W., M.A., G.D. analyzed
- 426 the data. A.S., G.G., T.H., F.F., MC. M. contributed new reagents/analytical tools.
- 427

428429 References

- 430
- 431 1. Plenge, R. M., Scolnick, E. M. & Altshuler, D. Validating therapeutic targets through human genetics.
 432 Nat. Rev. Drug Discov. 12, 581–594 (2013).
- 433 2. Adesuyan, M. *et al.* Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk
 434 of Alzheimer Disease. *Neurology* **102**, e209131 (2024).
- 435 3. Fang, J. *et al.* Endophenotype-based in silico network medicine discovery combined with insurance
 436 record data mining identifies sildenafil as a candidate drug for Alzheimer's disease. *Nat Aging* 1, 1175–
 437 1188 (2021).
- 438 4. Fang, J. *et al.* Artificial intelligence framework identifies candidate targets for drug repurposing in 439 Alzheimer's disease. *Alzheimer's Res Ther* **14**, 7 (2022).
- 5. Cheng, F. *et al.* Network medicine informed multi-omics integration identifies drug targets and repurposable medicines for Amyotrophic Lateral Sclerosis. (2024).doi:10.21203/rs.3.rs-4271755/v1

442 6. Cheng, F. *et al.* Artificial intelligence and open science in discovery of disease-modifying medicines for 443 Alzheimer's disease. *Cell Rep. Med.* **5**, 101379 (2024).

- 444 7. Wilson, J. L., Gravina, A. & Grimes, K. From random to predictive: a context-specific interaction
- framework improves selection of drug protein–protein interactions for unknown drug pathways. *Integr Biol* (2022).doi:10.1093/intbio/zyac002
- 447 8. Wilson, J. L. *et al.* A network paradigm predicts drug synergistic effects using downstream protein– 448 protein interactions. *Cpt Pharmacometrics Syst Pharmacol* (2022).doi:10.1002/psp4.12861
- 449 9. Ilieva, H., Vullaganti, M. & Kwan, J. Advances in molecular pathology, diagnosis, and treatment of 450 amyotrophic lateral sclerosis. *BMJ* **383**, e075037 (2023).
- 451 10. Ghasemi, M. & Brown, R. H. Genetics of Amyotrophic Lateral Sclerosis. *Cold Spring Harb. Perspect.* 452 *Med.* 8, a024125 (2018).
- 453 11. Zelic, M. *et al.* Glial state changes and neuroinflammatory RIPK1 signaling are a key feature of ALS
 454 pathogenesis. *bioRxiv* 2024.04.12.589201 (2024).doi:10.1101/2024.04.12.589201
- 455 12. Wilson, J. L., Wong, M., Stepanov, N., Petkovic, D. P. PhenClust, a standalone tool for identifying
 456 trends within sets of biological phenotypes using semantic similarity and the Unified Medical Language
 457 System. *JAMIA Open* 4, 00ab079 (2021).
- 458 13. Wilson, J. L. *et al.* PathFX provides mechanistic insights into drug efficacy and safety for regulatory 459 review and therapeutic development. *PLoS Comput Biol* **14**, e1006614 (2018).
- 460 14. Wilson, J. L. *et al.* PathFXweb: a web application for identifying drug safety and efficacy phenotypes.
 461 *Bioinformatics* **11**, 265–4506 (2019).
- 462 15. Wishart, D. S. *et al.* DrugBank: a comprehensive resource for in silico drug discovery and exploration.
 463 *Nucleic Acids Research* 34, D668-72 (2006).
- 464 16. Law, V. *et al.* DrugBank 4.0: shedding new light on drug metabolism. *Nucleic Acids Research* 42,
 465 D1091-7 (2014).
- 17. Tian, Y., of, M. S. I. journal & 2018 Evaluating large-scale propensity score performance through real world and synthetic data experiments. *academic.oup.com* at <<u>https://academic.oup.com/ije/article-</u>
 <u>abstract/47/6/2005/5043131></u>
- 18. Glynn, R. J., Schneeweiss, S. & Stürmer, T. Indications for propensity scores and review of their use
 in pharmacoepidemiology. *Basic Clin. Pharmacol. Toxicol.* **98**, 253–259 (2006).
- 471 19. Sekhon, J. S. Multivariate and Propensity Score Matching Software with Automated Balance
- 472 Optimization: The Matching Package for R. at
- 473 <<u>https://papers.ssrn.com/sol3/Delivery.cfm?abstractid=1009044></u>
- 474 20. Austin, P. C. The use of propensity score methods with survival or time-to-event outcomes: reporting 475 measures of effect similar to those used in randomized experiments. *Stat. Med.* **33**, 1242–1258 (2014).
- 476 21. Chen, Y.-W. *et al.* PharmOmics: A species- and tissue-specific drug signature database and gene-477 network-based drug repositioning tool. *iScience* **25**, 104052 (2022).
- 478 22. Keenan, A. B. *et al.* The Library of Integrated Network-Based Cellular Signatures NIH Program:
- 479 System-Level Cataloging of Human Cells Response to Perturbations. Cell Syst. 6, 13–24 (2018).

- 480
 23. Lin, X. & Qi, G. Observation on the efficacy of different methylprednisolone regimens in the treatment
 481 of myasthenia gravis. *Pak. J. Méd. Sci.* 38, 910–915 (2022).
- 482 24. Reimer, R. J. *et al.* An electronic health record cohort of Veterans with amyotrophic lateral sclerosis.
 483 *Amyotroph. Lateral Scler. Front. Degener.* 24, 695–701 (2023).
- 484 25. Suchard, M. A. et al. Comprehensive comparative effectiveness and safety of first-line
- 485 antihypertensive drug classes: a systematic, multinational, large-scale analysis. *The Lancet* **394**, 1816–
 486 (2019).
- 487 26. Bensimon, G., Lacomblez, L. & Meininger, V. A Controlled Trial of Riluzole in Amyotrophic Lateral
 488 Sclerosis. *N. Engl. J. Med.* 330, 585–591 (1994).
- 489 27. II, A. L. S. S. G. *et al.* Dose-ranging study of riluzole in amyotrophic lateral sclerosis. *Lancet* 347, 1425–1431 (1996).
- 491 28. Cedarbaum, J. M. *et al.* The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. *J. Neurol. Sci.* **169**, 13–21 (1999).
- 493 29. Abe, K. *et al.* Safety and efficacy of edaravone in well defined patients with amyotrophic lateral
 494 sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* 16, 505–512 (2017).
- 495 30. Paganoni, S. *et al.* Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. *N.* 496 *Engl. J. Med.* 383, 919–930 (2020).
- 497 31. Miller, T. M. *et al.* Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. *N. Engl. J. Med.* 387,
 498 1099–1110 (2022).
- 499 32. Brooks, B. R. *et al.* Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital
 500 capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. *PLoS ONE* 17,
 501 e0258614 (2022).
- 502 33. Arneson, D., Zhang, Y., Yang, X. & Narayanan, M. Shared mechanisms among neurodegenerative 503 diseases: from genetic factors to gene networks. *J. Genet.* **97**, 795–806 (2018).
- 504 34. Li, M. D., Burns, T. C., Morgan, A. A. & Khatri, P. Integrated multi-cohort transcriptional meta-analysis 505 of neurodegenerative diseases. *Acta Neuropathol. Commun.* **2**, 93 (2014).
- 506 35. Liddelow, S. A. *et al.* Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* **541**, 507 481–487 (2017).
- 508 36. Lawrence, J. M., Schardien, K., Wigdahl, B. & Nonnemacher, M. R. Roles of neuropathology-509 associated reactive astrocytes: a systematic review. *Acta Neuropathol. Commun.* **11**, 42 (2023).
- 510 37. Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. Sequence Variations in PCSK9, Low LDL, 511 and Protection against Coronary Heart Disease. *N. Engl. J. Med.* **354**, 1264–1272 (2006).
- 512 38. Horton, J. D., Cohen, J. C. & Hobbs, H. H. Molecular biology of PCSK9: its role in LDL metabolism. 513 *Trends Biochem. Sci.* **32**, 71–77 (2007).
- 514 39. Bowden, J. & Holmes, M. V. Meta-analysis and Mendelian randomization: A review. *Res. Synth.* 515 *Methods* **10**, 486–496 (2019).

- 516 40. Duffy, Á. *et al.* Tissue-specific genetic features inform prediction of drug side effects in clinical trials. 517 *Sci. Adv.* **6**, (2020).
- 518 41. Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P. & Ward, L. D. Phenotypes associated with genes
- 519 encoding drug targets are predictive of clinical trial side effects. *Nat. Commun.* **10**, 1579 (2019).

520

522 Tables

Pathway Name	ALS - HR	ALS - Cl low	ALS- CI high	MG - HR	MG - Cl low	MG - Cl high	PD - HR	PD - Cl low	PD - Cl high
CXCR5	1.151	1.021	1.298	1.143	1.052	1.241			
CXCR3	1.124	0.995	1.269	1.321	1.223	1.427			
Chemokine Pathways	1.123	1.018	1.239						
Neuropeptide Y	1.088	0.985	1.203						
CNR2	1.0.99	1.890	1.097						
Complement System	1.031	0.937	1.134	1.098	1.018	1.183	0.992	0.965	1.020

523

524 Table 1. Hazard ratios and confidence intervals for 6 drug classes across 3

525 **neurodegenerative indications.** ALS = Amyotrophic lateral sclerosis, MG = myasthenia gravis,

- 526 and PD = Parkinson's disease. CI = 95% confidence interval.
- 527

529 Figure Legends

530 Figure 1. A combined pathways and observational study approach for identifying pathways with 531 protective or harmful effects on overall survival in ALS. (A) Our overall workflow consisted of 'omics 532 data integration using several high-quality data sets, network modeling, identification of downstream 533 proteins, identifying patient cohorts, and effects estimation (B) For network inference, we modeled all 534 approved, active ingredients using ALS-PathFX and then created novel drug classes based on 535 downstream proteins included in drug networks. In this example, we assessed drugs with network 536 associations to multiple ALS sequencing datasets and included them in the "complement system" ("CS") 537 drug class if they had any complement-system proteins in their networks. We highlighted five drugs that 538 are associated with any one of two disease pathways (i.e., "ALS sequencing data 1", or "ALS sequencing 539 data 2"). In our schematic, we also highlighted that drugs "1", "2", and "3" contain downstream 540 associations to complement-system proteins and drugs "4" and "5" are connected to the same pathway 541 phenotypes, but through different proteins. Drugs, network proteins, and disease phenotypes are 542 represented by triangles, circles, or yellow boxes, respectively. (C) Later, we measured overall survival for 543 patients exposed to at least one of the "complement class" or "non-complement class" drugs using 544 observational studies in the Optum Market Clarity dataset. In this example, we grouped drugs "1", "2", and 545 "3" into the "target" class, and drugs "4" and "5" into the "comparator" class. We repeated this analysis for 546 6 drug classes and ranked classes by their effects on overall survival. Three complement proteins are 547 shown in the diagram, but a total of nine were considered when assigning drugs to the complement 548 system class: "Complement component 1, R subcomponent (C1R)"; "Complement component 1, S 549 subcomponent (C1S)"; "Complement component 1, Q subcomponent, alpha polypeptide (C1QA)"; 550 "Complement component 1, Q subcomponent, beta polypeptide (C1QB)" "Complement component 1, Q 551 subcomponent, alpha polypeptide (C1QA)"; "Complement component 1, Q subcomponent, gamma 552 polypeptide (C1QC)"; "Complement C3 (C3)"; "Complement C5 (C5)"; "Complement C3a receptor 1 553 (C3AR1)"; & "Complement C5a receptor 1 (C5AR1)". 554

Figure 2. ALS-PathFX connected acetophenazine to multiple neurodegenerative phenotypes.
PathFX connected the drug, acetophenazine (orange triangle) to four relevant neurodegenerative

557 phenotypes (green boxes): Alzheimer disease, Huntington's chorea, seq_data_1, and Multiple Sclerosis.

558 PathFX used three drug target proteins (red circles): androgen receptor (AR), and the dopamine

receptors D1 and D2 (DRD1, DRD2), and 99 adjacent proteins (gray ellipses) when predicting

560 associations to these phenotypes.

561

Figure 3. Patient cohorts in network drug classes have sufficient covariate balance (A) We plotted the total exposure days (sum of all prescriptions) per brand name per patient. We repeated this process for the target, CS-class (left) and comparator, non-CS-class (right) drugs. Each dot is a single patient. (B) The number of patients is plotted against their propensity score for patients on non-CS-class drugs (left) or CS-class drugs (right). The propensity score is the predicted probability using LogisticRegression on patient demographic, diagnostics, and medical prescription claims features. Patient demographics information for race (C) and gender (D) concepts.

569

570 Figure 3. Multiple network drug classes have effects on overall survival in ALS, myasthenia gravis 571 We plotted Kaplan Meier survival curves for the complement system class (A), the chemokine receptor 5 572 (CXCR5) class, a relatively high-risk class (B), and the chemokine pathway class, also a relatively-high-573 risk class (C) in ALS patients. We also plotted Kaplan Meier plots for three network classes in myasthenia 574 gravis patients: the complement system (D), chemokine receptor 5 (CXCR5) (E), and the chemokine 575 receptor 3 (CXCR3) (F) classes. In all plots, the proportion of the surviving population plotted against 576 time in days. Patients exposed to a "network class" or "Non-network class" drug are represented with a 577 dotted or solid line, respectively. Hazard ratio values with the 95% confidence interval for six network-578 drug classes (G) and their -log-(p-values) (H) as measured with weighted Cox proportional hazards 579 (coxph from the R survival package).

580

581 Figure 4. Complement-associated drugs activate multiple components of the complement

582 **pathway in ELISA assays.** Normalized values (to CTL: A1 cocktail factors) of fold change for the

583 complement factors C3, C4, and Factor B following treatment of human iPSC astrocytes with the A1

584 cocktail factors and selective classes of compounds (100 nM, 1 μ M and 10 μ M). Addition of

- 585 methylprednisolone, mirtazapine and albuterol showed the strongest effect in increasing the complement
- 586 levels (especially C3).
- 587

588 Supplementary Material

- 589 Supplemental File 1 extended methods, results, Tables S1-8, Figures S1-32.
- 590 Supplemental File 2 ALS-PathFX pathways, all modeling results.
- 591 Supplemental File 3 All network-protein derived drug classes.
- 592 Supplemental File 4 Drug brand names, prescription days, patient demographic data, and covariates for
- 593 the study of ALS patients and the CS-class.
- 594 Supplemental File 5 All diagnosis codes used to select patients.
- 595 Supplemental File 6 Drug brand names, prescription days, patient demographic data, and covariates for
- 596 the study of ALS patients and the CXC-class.
- 597 Supplemental File 7 Drug brand names, prescription days, patient demographic data, and covariates for
- 598 the study of ALS patients and the CXCR3-class.
- 599 Supplemental File 8 Drug brand names, prescription days, patient demographic data, and covariates for
- 600 the study of ALS patients and the CXCR5-class.
- 601 Supplemental File 9 Drug brand names, prescription days, patient demographic data, and covariates for
- 602 the study of ALS patients and the CNR2-class.
- 603 Supplemental File 10 Drug brand names, prescription days, patient demographic data, and covariates
- 604 for the study of ALS patients and the NPY-class.
- 605 Supplemental File 11 PathFX predictions for multiple neurodegenerative diseases.
- 606 Supplemental File 12 Drug brand names, prescription days, patient demographic data, and covariates
- 607 for the study of MG patients and the CXCR5-class.
- 608 Supplemental File 13 Drug brand names, prescription days, patient demographic data, and covariates
- 609 for the study of MG patients and the CXCR3-class.
- 610 Supplemental File 14 Drug brand names, prescription days, patient demographic data, and covariates
- 611 for the study of MG patients and the CS-class.

- 612 Supplemental File 15 Drug brand names, prescription days, patient demographic data, and covariates
- 613 for the study of PD patients and the CS-class.
- 614 Supplemental File 16 Table of hazard ratios and confidence intervals for all studies.









Pathway Name	ALS - HR	ALS - CI low	ALS- Cl high	MG - HR	MG - CI low	MG - Cl high	PD - HR	PD - Cl low	PD - Cl high
CXCR5	1.151	1.021	1.298	1.143	1.052	1.241			
CXCR3	1.124	0.995	1.269	1.321	1.223	1.427			
Chemokine Pathways	1.123	1.018	1.239						
Neuropeptide Y	1.088	0.985	1.203						
CNR2	1.0.99	1.890	1.097						
Complement System	1.031	0.937	1.134	1.098	1.018	1.183	0.992	0.965	1.020

